Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNV3
- Development stage
- Phase 2
- Lead developer
- Zhejiang Shimai Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral (intravenous Injection)
01
Overview
DNV3 is a human monoclonal antibody targeting lymphocyte activation gene 3 (LAG-3, also known as CD223). It functions as an immune checkpoint inhibitor by blocking LAG-3, thereby enhancing T cell activation and anti-tumor immune responses. The drug exerts its effects through mechanisms including inhibition of the CD223 antigen (LAG-3), stimulation of T lymphocytes, and antibody-dependent cell cytotoxicity (ADCC). Developed by Zhejiang Shimai Pharmaceutical, DNV3 is being investigated primarily for the treatment of advanced or metastatic solid tumors and lymphoma. Clinical trials are ongoing in China for these indications, with additional early-phase studies in multiple sclerosis[1][2][7].
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on DNV3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNV3.